SPAC1039.01 Antibody

What is SPAC1039.01 Antibody and what organism does it target?

SPAC1039.01 Antibody (Product Code: CSB-PA890794XA01SXV) is a polyclonal antibody raised in rabbits against recombinant Schizosaccharomyces pombe (strain 972 / ATCC 24843) SPAC1039.01 protein. This antibody specifically targets the SPAC1039.01 protein in fission yeast (S. pombe), which is identified by the UniProt accession number Q9US40. The antibody is produced through immunization with a recombinant version of the target protein and is subsequently purified using antigen affinity chromatography to ensure high specificity and minimal cross-reactivity .

What are the validated applications for SPAC1039.01 Antibody in research?

Based on current validation data, SPAC1039.01 Antibody has been tested and confirmed effective for ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot (WB) applications. These applications allow researchers to detect and quantify the presence of SPAC1039.01 protein in various experimental contexts. The antibody's specificity for S. pombe strain 972 / ATCC 24843 makes it particularly valuable for researchers studying protein expression and function in this model organism . Similar to other research antibodies, experimental validation in specific research contexts is recommended, as application effectiveness may vary depending on experimental conditions.

How does the polyclonal nature of SPAC1039.01 Antibody impact experimental design?

SPAC1039.01 Antibody is a polyclonal IgG antibody, meaning it contains a heterogeneous mixture of antibodies that recognize different epitopes on the target protein. This polyclonal nature offers several experimental advantages and considerations:

• Enhanced sensitivity: Multiple epitope recognition typically provides stronger signal detection compared to monoclonal antibodies

• Robustness to protein denaturation: Recognition of multiple epitopes increases the likelihood of detection even if some epitopes are affected by experimental conditions

• Batch variation consideration: Each production lot may have slight variations in epitope recognition profiles

• Cross-reactivity potential: Broader epitope recognition increases the possibility of cross-reactivity with structurally similar proteins

Researchers should design appropriate controls to account for these characteristics, particularly when transitioning between different antibody lots or when high specificity is critical for experimental outcomes .

What are the optimal storage conditions for maintaining SPAC1039.01 Antibody activity?

The manufacturer recommends storing SPAC1039.01 Antibody at either -20°C or -80°C upon receipt. The antibody should not be subjected to repeated freeze-thaw cycles as this can significantly degrade antibody quality and performance. The antibody is supplied in a stabilizing buffer containing 50% glycerol, 0.01M PBS (pH 7.4), and 0.03% Proclin 300 as a preservative. This formulation helps maintain antibody stability during storage .

For researchers working with this antibody over extended periods, the following protocol is recommended to minimize freeze-thaw cycles:

Table 1: Recommended Antibody Aliquoting Protocol

Following this protocol will help maintain antibody performance across experiments and extend the usable lifetime of the reagent .

How should researchers optimize Western blot protocols for SPAC1039.01 Antibody?

When optimizing Western blot protocols for SPAC1039.01 Antibody, researchers should consider several critical parameters that may affect detection sensitivity and specificity:

• Sample preparation: For optimal detection of SPAC1039.01 in S. pombe lysates, use a lysis buffer containing protease inhibitors to prevent degradation of the target protein. Cell disruption methods such as glass bead lysis are typically effective for yeast samples.

• Blocking optimization: Test both BSA and non-fat dry milk as blocking agents, as polyclonal antibodies may perform differently with each. A suggested starting protocol:

  • Block membrane in 5% blocking agent in TBST for 1 hour at room temperature

  • Compare results between experiments to determine optimal blocking conditions

• Antibody dilution optimization: Begin with a 1:1000 dilution in blocking buffer and adjust based on signal-to-noise ratio. A dilution series experiment is recommended:

Table 2: Suggested Antibody Dilution Series for Optimization

• Detection system selection: For polyclonal antibodies like SPAC1039.01 Antibody, HRP-conjugated anti-rabbit secondary antibodies are suitable. Enhanced chemiluminescence (ECL) detection systems typically provide good sensitivity while allowing for exposure time optimization .

This methodological approach mirrors techniques used in successful antibody characterization studies, such as those employing capture-purification of antibodies directly onto biosensor chips for functional binding analysis .

What controls should be included when using SPAC1039.01 Antibody in immunoassays?

When designing immunoassays with SPAC1039.01 Antibody, incorporating appropriate controls is essential for result validation and troubleshooting:

• Positive control: Include lysate from wild-type S. pombe (strain 972 / ATCC 24843) known to express SPAC1039.01 protein. This confirms antibody functionality and establishes expected signal intensity.

• Negative control: Use one of the following:

  • Lysate from a SPAC1039.01 knockout S. pombe strain (if available)

  • Lysate from another yeast species (e.g., S. cerevisiae) where the antibody should not react

  • Pre-immune serum control at the same concentration as the primary antibody

• Loading control: Include detection of a constitutively expressed S. pombe protein (e.g., actin or tubulin) to verify equal loading across samples. This is particularly important when comparing SPAC1039.01 expression levels between different conditions.

• Secondary antibody-only control: Omit primary antibody but include secondary antibody to identify potential non-specific binding of the secondary antibody.

• Peptide competition assay: Pre-incubate the antibody with excess recombinant SPAC1039.01 protein before use in the immunoassay. Signal reduction confirms specific binding to the target protein.

This comprehensive control strategy is similar to approaches used in antibody validation for virus neutralization studies, where specificity validation is critical for result interpretation .

How can SPAC1039.01 Antibody be used to study protein-protein interactions in S. pombe?

SPAC1039.01 Antibody can be employed in several advanced techniques to investigate protein-protein interactions:

• Co-immunoprecipitation (Co-IP): The antibody can be used to pull down SPAC1039.01 protein complexes from S. pombe lysates. Any interacting proteins will co-precipitate and can be identified by:

  • Western blotting (if candidate interactors are known)

  • Mass spectrometry (for unbiased discovery of novel interactors)

  Protocol considerations: Optimize lysis conditions to preserve native protein interactions. Mild detergents (0.1-0.5% NP-40 or Triton X-100) are typically suitable starting points.

• Proximity-based labeling: Combine SPAC1039.01 Antibody with techniques such as BioID or APEX2 proximity labeling to identify proteins in close spatial proximity to SPAC1039.01 in living cells.

• Single-molecule approaches: Based on methods similar to those described for receptor studies using optical tweezers, SPAC1039.01 Antibody could be conjugated to microspheres to study molecular interactions at the single-molecule level .

The following table outlines key parameters for Co-IP optimization:

Table 3: Co-IP Optimization Parameters for SPAC1039.01 Antibody

These methodological approaches can be integrated with techniques used to characterize antibody-antigen interactions, such as biolayer interferometry (BLI) described in the SARS-CoV-2 antibody research .

How reliable is SPAC1039.01 Antibody for quantifying protein expression levels?

Quantifying protein expression using SPAC1039.01 Antibody requires careful consideration of several factors that influence quantitative reliability:

• Linear detection range: Polyclonal antibodies typically offer good sensitivity but may have a narrower linear range for quantification compared to monoclonal antibodies. Researchers should:

  • Perform a standard curve using purified recombinant SPAC1039.01 protein (if available)

  • Determine the linear range by analyzing serial dilutions of positive control samples

  • Ensure experimental samples fall within this established linear range

• Normalization strategies: To account for technical variations, implement:

  • Loading controls (housekeeping proteins)

  • Total protein normalization (e.g., using stain-free technology or Ponceau staining)

  • Internal calibration standards

• Detection method selection: Different detection methods offer varying quantitative capabilities:

  • Chemiluminescence: Wide dynamic range but may saturate at high expression levels

  • Fluorescence-based detection: Generally offers superior linearity for quantification

  • Colorimetric methods: Limited dynamic range but simple implementation

• Batch consistency: When comparing samples across multiple experiments:

  • Include a common reference sample in each experiment

  • Consider using the same lot of antibody when possible

  • Apply batch correction algorithms during data analysis

Similar quantitative considerations have been applied in studies using antibodies for viral neutralization assays, where precise quantification of binding and neutralizing capacity is essential .

Can SPAC1039.01 Antibody be used for analyzing post-translational modifications?

The suitability of SPAC1039.01 Antibody for detecting post-translational modifications (PTMs) depends on several factors:

This approach builds upon techniques used in comprehensive antibody characterization studies, where detailed epitope mapping can inform antibody selection for specific analytical applications .

What are the most common causes of weak or absent signal when using SPAC1039.01 Antibody?

When experiencing weak or absent signals with SPAC1039.01 Antibody, researchers should systematically evaluate the following potential causes and solutions:

Table 4: Troubleshooting Guide for Weak or Absent Signal

Each potential issue should be systematically addressed, starting with verification of antibody quality and experimental conditions. For particularly challenging samples, consider using signal enhancement methods such as tyramide signal amplification (TSA) or increasing the antibody concentration for initial troubleshooting .

How can researchers address non-specific binding when using SPAC1039.01 Antibody?

Non-specific binding is a common challenge with polyclonal antibodies like SPAC1039.01 Antibody. Researchers can implement the following strategies to minimize this issue:

• Optimize blocking conditions:

  • Test different blocking agents (BSA, non-fat dry milk, commercial blocking buffers)

  • Increase blocking time (from 1 hour to overnight) at 4°C

  • Add 0.1-0.5% Tween-20 to reduce hydrophobic interactions

• Adjust antibody incubation parameters:

  • Dilute antibody in fresh blocking buffer

  • Reduce primary antibody concentration

  • Perform incubations at 4°C overnight rather than at room temperature

• Modify wash protocols:

  • Increase wash duration and number of washes

  • Add higher concentration of detergent (0.1-0.5% Tween-20) to wash buffers

  • Use high-salt wash buffers (up to 500 mM NaCl) for one or more washes

• Pre-adsorption technique:

  • Incubate diluted antibody with a membrane containing non-target proteins

  • Remove antibodies bound to non-specific proteins before applying to the experimental membrane

• Peptide competition:

  • Incubate antibody with excess recombinant SPAC1039.01 protein

  • Apply to duplicate blots to distinguish specific from non-specific binding

Similar approaches for minimizing non-specific binding have been successfully employed in antibody screening and characterization studies for other target proteins .

How can SPAC1039.01 Antibody contribute to studying protein localization in S. pombe?

SPAC1039.01 Antibody can be utilized for studying protein localization through several immunological techniques, with appropriate optimization:

• Immunofluorescence microscopy:

  • Fixation method optimization: Test both formaldehyde (3-4%) and methanol fixation

  • Cell wall digestion: Optimize zymolyase treatment (5-10 units/mL, 10-30 minutes)

  • Antibody penetration: Include 0.1% Triton X-100 in blocking and antibody solutions

  • Signal amplification: Consider tyramide signal amplification for low-abundance proteins

• Subcellular fractionation combined with Western blotting:

  • Separate nuclear, cytoplasmic, membrane, and organelle fractions

  • Perform Western blotting with SPAC1039.01 Antibody on each fraction

  • Include fraction-specific marker proteins (e.g., histone H3 for nuclear fraction)

• Proximity ligation assay (PLA):

  • Combine SPAC1039.01 Antibody with antibodies against potential interacting partners

  • Visualize interactions in situ with specialized PLA reagents

  • Quantify interaction signals in different cellular compartments

• Electron microscopy immunogold labeling:

  • Conjugate SPAC1039.01 Antibody to gold particles

  • Apply to ultrathin sections of S. pombe cells

  • Visualize precise subcellular localization at ultrastructural level

These approaches draw on principles similar to those used in advanced antibody characterization studies and can be adapted to S. pombe-specific research requirements .

How does epitope recognition by SPAC1039.01 Antibody impact experimental design for mutational studies?

When designing mutational studies involving SPAC1039.01 protein, researchers must consider how mutations might affect epitope recognition by the polyclonal antibody:

• Epitope prediction and mutation design:

  • Since SPAC1039.01 Antibody was raised against the full recombinant protein, it likely recognizes multiple epitopes

  • Mutations concentrated in a single domain may still allow detection by antibodies targeting other regions

  • Analyze the protein sequence for potential antigenic regions using epitope prediction algorithms

• Validation strategy for mutated constructs:

  • Express wild-type and mutant proteins with epitope tags (e.g., FLAG, HA)

  • Compare detection patterns between SPAC1039.01 Antibody and tag-specific antibodies

  • Identify mutations that affect antibody recognition versus those that don't

• Experimental controls for mutational studies:

  • Include both wild-type and complete knockout controls

  • For each mutation, analyze protein expression using both SPAC1039.01 Antibody and tag antibodies

  • Consider using alternative detection methods (e.g., mass spectrometry) for mutations affecting critical epitopes

• Domain-specific mutation effects:

Table 5: Strategic Approach to Mutational Analysis

This strategic approach to mutation analysis has parallels in antibody engineering studies, where understanding epitope recognition is crucial for interpreting experimental outcomes .